3 citations
,
June 2023 in “Frontiers in medicine” This review discusses the association between oxidative stress and alopecia areata while proposing antioxidants as a potential supplementary therapy, but it reports no new clinical results.
3 citations
,
January 2023 in “Dermatology Practical & Conceptual” In this study, the researchers reported that ischemia-modified albumin and IMA/albumin levels may not effectively predict disease severity in patients with alopecia areata.
4 citations
,
October 2022 in “Genes” This review discusses the role of cutaneous and intestinal microbiota in the development of alopecia areata, summarizing current literature without reporting new clinical results.
11 citations
,
June 2022 in “Frontiers in immunology” This review discusses the challenges in identifying specific hair follicle antigens involved in initiating alopecia areata and highlights the need for further research to understand its etiopathogenesis, reporting no new results.
3 citations
,
April 2022 in “Microorganisms” This study found that the scalp microbiome was more diverse in alopecia areata patients than in healthy controls, and distinctive microbial profiles may be linked to disease severity and prognosis.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
117 citations
,
July 2021 in “British Journal of Dermatology” This study reports that the incidence of alopecia areata is 0.26 per 1000 person-years in the UK, with higher rates among Asian ethnic groups, socially deprived populations, and urban residents.
134 citations
,
July 2020 in “Experimental dermatology” This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.
22 citations
,
April 2020 in “Frontiers in Cellular and Infection Microbiology” This study found significant differences in scalp microbiome composition and volatile organic metabolites between individuals with alopecia areata and healthy controls, suggesting potential microbiome-related therapeutic interventions for hair growth disorders.
17 citations
,
April 2020 in “Dermatology and Therapy” In this randomized double-blind study, 160 adults with alopecia areata showed significant improvements in hair loss severity after using a bioactive peptide cosmetic product that mimics platelet-rich plasma, while the placebo group showed no significant change, underlining the treatment's potential effectiveness.
19 citations
,
December 2019 in “Journal of the American Academy of Dermatology” This study suggests that intralesional triamcinolone acetonide at a concentration of 5 mg/mL may offer the best balance of effectiveness and safety for treating focal alopecia areata.
55 citations
,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This review discusses emerging research areas in alopecia areata pathobiology, highlighting the potential roles of unconventional immune cells and the need for more targeted therapeutic strategies, but reports no new experimental results.
30 citations
,
July 2019 in “PloS one” This study found that T-regulatory cells, specifically the FOXP3 CD39 subset, were significantly reduced in both circulation and hair follicles of alopecia areata patients compared to healthy subjects, suggesting potential therapeutic targets.
21 citations
,
April 2019 in “Journal of cutaneous pathology” This study found a significant reduction in Treg cell frequency in alopecia areata compared to other autoimmune and non-autoimmune skin diseases using immunohistochemical staining.
73 citations
,
April 2019 in “Experimental Dermatology” This review explores the hair follicle microbiome's interaction with the immune system, discussing its potential clinical implications for scalp health and disease but reports no new clinical results.
48 citations
,
April 2019 in “PloS one” This study observed a microbial shift on the scalp of Alopecia areata patients, characterized by an increase in Propionibacterium acnes and a decrease in Staphylococcus epidermidis, compared to healthy controls.
20 citations
,
March 2019 in “Journal of The European Academy of Dermatology and Venereology” In this study, 5% minoxidil significantly improved outcomes for children and adults with patchy alopecia areata compared to placebo, with moderate quality evidence and no severe adverse events reported, though more research is needed to address remaining uncertainties.
130 citations
,
February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.
56 citations
,
January 2019 in “Lancet” This review discusses the emerging use of JAK inhibitors in alopecia areata treatment and reports no new clinical results; it highlights hair regrowth despite symptom recurrence after stopping therapy.
191 citations
,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.
42 citations
,
March 2018 in “PLOS Biology” This study found that autophagy plays a novel role in human hair growth, with altered autophagic flux during hair development phases influencing hair follicle behavior in a preclinical model.
24 citations
,
March 2018 in “Experimental Dermatology” This review explores the role of regulatory T cells in autoimmune skin disorders like alopecia areata and vitiligo, emphasizing unanswered questions and reporting no new experimental results.
9 citations
,
December 2017 in “The Journal of Allergy and Clinical Immunology” This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.
51 citations
,
December 2017 in “Skin Appendage Disorders” This review examines the literature on autoimmune hair loss disorders, highlighting the collapse of immune privilege and the potential role of neurogenic stress in this process, but reports no new clinical results.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.
290 citations
,
December 2017 in “Journal of The American Academy of Dermatology” This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.
99 citations
,
July 2017 in “Clinical Reviews in Allergy & Immunology” This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.
95 citations
,
July 2016 in “Journal of The American Academy of Dermatology” This review concluded that patients with alopecia areata consistently show poor health-related quality of life scores, similar to those in other chronic skin diseases like atopic dermatitis and psoriasis.
50 citations
,
January 2016 in “Journal of the American Academy of Dermatology” This systematic review of pulse corticosteroid therapy for alopecia areata found relatively low complete response rates, but responders experienced low relapse rates, indicating potential benefits for patients with favorable prognostic factors.
144 citations
,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.
62 citations
,
June 2015 in “The Journal of Dermatology” This study found that patients with alopecia areata had higher levels of Th17 cells and lower levels of regulatory T cells compared to healthy controls, suggesting an immune imbalance in these patients.
45 citations
,
December 2014 in “Journal of the European Academy of Dermatology and Venereology” This study found that plasmacytoid dendritic cells are central to the pathogenesis of alopecia areata, suggesting they may help differentiate it from trichotillomania and androgenetic alopecia.
23 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” This study highlights rapid advances in alopecia areata treatment following the identification of genetic variants associated with increased disease risk, suggesting potential for precision medicine approaches.
26 citations
,
September 2013 in “Journal of Dermatological Science” In this study, researchers found that serum granulysin levels might serve as a novel marker for disease activity in acute alopecia areata, being significantly associated with broader bald skin areas, poorer prognosis, and co-existing allergic disorders.
18 citations
,
July 2013 in “Journal of Leukocyte Biology” The study suggests that vaccination with soluble keratin peptides K71 and K31 significantly delayed the onset and progression of autoimmune alopecia areata in mice by inducing T cell anergy.
421 citations
,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
66 citations
,
July 2010 in “Journal of Proteome Research” This study suggests that an immune response to trichohyalin and keratin 16 may contribute to the pathogenesis of alopecia areata.
717 citations
,
June 2010 in “Nature” This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.
52 citations
,
March 2010 in “British Journal of Dermatology” This study demonstrated the expression of type 1 interferon-related proteins in inflammatory lesions of alopecia areata, showing a distinct distribution pattern compared to cicatricial alopecia.
35 citations
,
August 2009 in “Journal of the American Academy of Dermatology” This study found a decreased number of follicular melanocytes in patients with alopecia areata, though it remains unclear if this decrease is due to autoimmune attack or rapid hair cycling.
286 citations
,
August 2007 in “Journal of Clinical Investigation” This review examines the interplay of genetics and neuroimmunology in alopecia areata, highlighting its potential to inform broader autoimmunity research, but reports no new findings.
16 citations
,
April 2007 in “Journal of Medical Primatology” This study reports that a 14-year-old female rhesus monkey with alopecia universalis was found to have a T-cell-mediated autoimmune disease similar to human alopecia areata universalis.
151 citations
,
February 2007 in “International Journal of Dermatology” This review explores the causes and mechanisms of alopecia areata and discusses current treatments, reporting no new clinical findings.
185 citations
,
August 2005 in “Autoimmunity Reviews” This review discusses alopecia areata as a model for studying tissue-directed autoimmune diseases and reports no new clinical findings.
38 citations
,
September 2004 in “Journal of Autoimmunity” Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.
114 citations
,
August 2002 in “Journal of Investigative Dermatology” Alopecia areata is caused by an immune response, and targeting immune cells might help treat it.
77 citations
,
June 2002 in “Journal of Investigative Dermatology” CD44 variant changes start alopecia areata, but don't maintain it.
127 citations
,
January 2000 in “Journal of Investigative Dermatology” This study found that pro-inflammatory cytokines and apoptotic mechanisms, specifically involving granzyme B and Fas pathways, are associated with chronic alopecia areata, indicating their potential role in the disease's persistence.
71 citations
,
January 1998 in “Pathobiology” This review discusses the use of animal models to study alopecia areata and reports no new experimental results, emphasizing the potential for these models to explore the disease's genetics and treatment.
178 citations
,
June 1994 in “Journal of Investigative Dermatology” This study found that a non-scarring alopecia in C3H/HeJ mice resembles human alopecia areata and may serve as a valuable model for studying specific subtypes of the human condition.
78 citations
,
July 1984 in “Journal of Investigative Dermatology”